Clinical Evidence: What the Trials Really Show
Weight Loss Results: Wegovy and Mounjaro Doses Evidence
The clinical evidence for Wegovy and Mounjaro doses reveals distinct but impressive weight management outcomes from major pharmaceutical trials. Wegovy's STEP programme demonstrated that patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results represent some of the most robust weight management data available for GLP-1 treatments in the UK.
Mounjaro's clinical programme focused on tirzepatide, a dual GIP/GLP-1 receptor agonist with its own distinct trial outcomes. Both Wegovy and Mounjaro doses follow carefully structured escalation schedules designed to minimise side effects while optimising weight management benefits. The key difference lies in their mechanisms: Wegovy targets GLP-1 receptors exclusively, while Mounjaro activates both GIP and GLP-1 pathways. Both treatments are available from EverydayMeds, and your prescriber can help determine which clinical profile aligns with your weight management goals.
Wegovy and Mounjaro Doses: Pricing and Value Comparison
Understanding the cost structure for Wegovy and Mounjaro doses helps you plan your weight management investment effectively. Wegovy starts at £79.99 for the 0.25mg starter dose after applying your FIRST40 discount code at checkout, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). Our bundle options provide convenient multi-month supplies, such as the Intro Trio covering your first three dose escalations for £299.99.
Mounjaro follows its own pricing structure with similar dose escalation requirements and bundle availability. Both treatments require the same rigorous clinical assessment process and prescriber approval before dispatch. New customers use code FIRST40 while returning customers apply DOSE25 at checkout to access these competitive prices. The investment in either treatment should be viewed as part of a comprehensive weight management programme that includes dietary changes and increased physical activity as outlined in the clinical trials.
STEP Trial Results for Wegovy and Mounjaro Doses Context
The landmark STEP trials provide the strongest evidence base for understanding Wegovy's weight management potential when compared to other treatments like Mounjaro. STEP 1 showed approximately 15% average weight loss, STEP 3 achieved around 16% with intensive behavioural therapy, and STEP 5 maintained clinically studied weight loss at two years. These results were achieved by patients following structured dose escalation schedules alongside comprehensive lifestyle modifications.
The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, adding important health benefits beyond weight management alone. When comparing these results to Mounjaro's trial data, it's important to note that different study designs, populations, and endpoints make direct percentage comparisons inappropriate. Both treatments have demonstrated clinically meaningful weight management benefits in their respective programmes.
How Wegovy and Mounjaro Doses Work Differently
The fundamental difference between Wegovy and Mounjaro doses lies in their receptor targeting and subsequent physiological effects. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone, reducing appetite and promoting satiety after smaller meals. This mechanism helps many patients naturally reduce their caloric intake without the constant hunger that often sabotages traditional dieting efforts. Mounjaro's tirzepatide targets both GIP and GLP-1 receptors, creating a dual pathway approach to weight management with its own distinct physiological profile. Both work on brain appetite centres to help reduce food cravings, but their different receptor activity may suit different patient profiles and treatment goals.
Ordering Wegovy and Mounjaro Doses Through EverydayMeds
Our streamlined ordering process for both Wegovy and Mounjaro doses begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Your responses are reviewed by our qualified prescribers within three working days (or 24 hours with express service) to determine suitability and appropriate starting doses. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our UK-registered pharmacy (GPhC #9012878) ensures full regulatory compliance and professional oversight throughout your treatment journey. Each delivery includes detailed administration guidance and ongoing support from our clinical team.
Storage and Practical Considerations for Wegovy and Mounjaro Doses
Proper storage significantly impacts the effectiveness of both Wegovy and Mounjaro doses, with some key differences worth noting. Both require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks of room temperature stability below 30°C compared to Mounjaro's 21-day limit. The FlexTouch pen system used by Wegovy provides precise dose delivery with clear visual confirmation of injection completion. Dose escalation schedules cannot be abbreviated for either treatment - the gradual increase from starter doses to maintenance levels minimises gastrointestinal side effects while optimising therapeutic benefits. Both treatments require once-weekly administration on the same day each week for optimal results.
Real-World Weight Loss Results: Wegovy and Mounjaro Doses in UK Practice
Beyond clinical trials, understanding how Wegovy and Mounjaro doses perform in real-world UK settings provides valuable context for treatment expectations. Post-marketing surveillance and patient registries continue to collect data on long-term outcomes, adherence rates, and practical challenges faced by UK patients. The structured dose escalation required for both treatments helps healthcare providers monitor progress and adjust expectations based on individual responses.
Patient success with either treatment depends heavily on concurrent lifestyle modifications including reduced-calorie diets and increased physical activity as demonstrated in the pivotal trials. The weight regain observed in STEP trial extensions, where patients regained approximately two-thirds of lost weight within one year of stopping, emphasises that weight management represents a long-term commitment rather than a temporary intervention. Both Wegovy and Mounjaro are designed as part of comprehensive weight management strategies rather than standalone solutions.
Choosing Between Wegovy and Mounjaro Doses: Clinical Guidance
Your prescriber will consider multiple factors when recommending between Wegovy and Mounjaro doses, including your medical history, previous weight management attempts, concurrent medications, and treatment goals. Neither treatment is inherently superior - they represent different approaches to weight management with distinct mechanisms and clinical profiles. Some patients may respond better to Wegovy's GLP-1-focused approach, while others might benefit from Mounjaro's dual receptor targeting. Your clinical assessment helps identify which treatment aligns best with your individual circumstances and health objectives. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which is right for you based on comprehensive evaluation of your medical profile and weight management needs. Start your assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients at https://everydaymeds.co.uk/collections/wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
